Umbilical cord blood−derived natural killer cells as a viable and potent source for adoptive cell therapy
These findings support the feasibility of producing cryopreserved, UCB-derived NK cells as a stable and effective "off-the-shelf" product for adoptive immunotherapy, particularly in the treatment of acute myeloid leukemia, with advantages in scalability, standardization, and rapid clinical deployment.
Authors
- Julia T. Cottas de Azevedo
- Raquel de Melo Alves-Paiva
- Larissa Leggieri Coa (ORCID: https://orcid.org/0000-0002-1764-473X)
- Larissa C. Zanetti (ORCID: https://orcid.org/0000-0003-1716-7301)
- Jamile Ramos da Silva (ORCID: https://orcid.org/0000-0002-1945-7049)
- Micheli S. Sielski (ORCID: https://orcid.org/0000-0002-6682-7954)
- José Mauro Kutner (ORCID: https://orcid.org/0000-0003-3784-6731)
- DC Oliveira
- Juliana A. P de Godoy
- Nelson Hamerschlak
- Lucila N. Kerbauy
- Oswaldo Keith Okamoto
Institutions
- Hospital Israelita Albert Einstein (BR)
Publication Details
- Journal
- Cytotherapy
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1016/j.jcyt.2026.102079
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sociedade Beneficente Israelita Brasileira Albert Einstein